skip to main content

MG – MGTX Trial — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

HardPeripheral Neuropathy & NeuromuscularMG – MGTX TrialSCE Neurology

A 45-year-old woman with AChR-positive MG without thymoma asks about thymectomy. What did the MGTX trial show?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: AThymectomy plus prednisolone improved outcomes and reduced steroid requirements vs prednisolone alone

The best answer is “Thymectomy plus prednisolone improved outcomes and reduced steroid requirements vs prednisolone alone”. Neuromuscular diagnosis combines distribution, reflexes, sensation, electrophysiology, laboratory, antibody, imaging and genetic findings; testing should resolve a live diagnostic or treatment decision rather than repeat established evidence. The alternatives “No benefit, after specialist assessment, when the phenotype supports it”, “for thymomatous MG, when the phenotype supports it, within the relevant UK pathway”, “Worsens MG, within the relevant UK pathway, after excluding important mimics”, “for MuSK-MG, after excluding important mimics, after specialist assessment, when the phenotype supports it” are clinically adjacent possibilities, but they do not match the defining chronology, localisation, physiology, investigation result or UK management sequence in this stem.

Reference: JNNP specialist neuromuscular literature: https://jnnp.bmj.com/